undamentalytics Newsletter
Sign in

Immix Biopharma, Inc. (IMMX) stock

Add to watchlist

Add holding +

NASDAQ: IMMX Nasdaq Biotechnology Next results ~November 6, 2026

Immix Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds78 adding, 24 cuttingOf 25 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 6, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Immix Biopharma, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 84% and a beta of 1.6 against the S&P 500.
  • Heavily shorted. 15.2% of the shares available to trade are sold short (6.2 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share
-$0.18 against an average estimate of -$0.18: missed by 2.4%
Next report
November 6, 2026; average EPS estimate -$0.19

Immix Biopharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.5%
  • 1 week-9.9%
  • 1 month-25.0%
  • This year+38.8%
  • 1 year+91.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Immix Biopharma, Inc. valuation models and calculator

No model value for Immix Biopharma, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 6, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.19 (range −$0.21 to −$0.17) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.72 +19% — 0%
Next −$0.95 −31% $28m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.3% on 90 days ago. In the last 30 days, 2 analysts raised Immix Biopharma, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Immix Biopharma, Inc., last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.70 Current fiscal year, 60 days ago: −$0.74 Current fiscal year, 30 days ago: −$0.72 Current fiscal year, 7 days ago: −$0.72 Current fiscal year, Now: −$0.72 −$0.72 Next fiscal year, 90 days ago: −$0.84 Next fiscal year, 60 days ago: −$0.90 Next fiscal year, 30 days ago: −$0.86 Next fiscal year, 7 days ago: −$0.95 Next fiscal year, Now: −$0.95 −$0.95

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.70−$0.84
60 days ago −$0.74−$0.90
30 days ago −$0.72−$0.86
7 days ago −$0.72−$0.95
Now −$0.72−$0.95

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.18 −$0.18 −2.4%
Mar 2026 −$0.21 −$0.18 +13.2%
Dec 2025 −$0.16 −$0.28 −75.0%
Sept 2025 −$0.19 −$0.24 −26.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026347
  2. Sep 2026347
  3. Aug 2026347
  4. Jul 2026347

Counts of recommendations published by analysts covering Immix Biopharma, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.2%
of tradable shares
Days to cover
6.2
at average volume
Short interest, 1 month
+11%
to October 15, 2026
Held by institutions
69%
of shares
Held by insiders
14.8%
of shares
Employees
21
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
IMMX−36%+202%−68%+138%+39%
Industry peers (median)−57%−18%−28%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
IMMX42%58%42%50%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
IMMX−89%−49%−81%−42%−50%
S&P 500−25%−10%−8%−19%−9%

Worst fall since December 16, 2021: 89% from January 5, 2022 to November 10, 2022. Getting back needed a 800% gain, reached on December 15, 2023, 400 days after the low.

Price behaviour

52-week range
$3.03 – $14.47
From 52-week high
−49.8%
vs 50-day average
−33.4%
vs 200-day average
−23.5%
Volatility (1 year)
84%
Beta vs S&P 500
1.60

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$580M
Institutions reporting
109
Shares held vs prior quarter
▲ 107.6%
Positions opened / closed
43 / 11

Top buyers and sellers, Q2 2026: 78 institutions bought and 24 sold ; the biggest buyer was State Street Corp (+2.8M shares) and the biggest seller Susquehanna International Group, LLP (−433K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jupiter Topco LLC $101M 9.8M 17.4% —
Saturn V Capital Management LP $48M 4.7M 8.3% ▲ 26.1%
Eventide Asset Management, LLC $40.1M 3.9M 6.9% ▲ 52.6%
State Street Corp $30.9M 3.0M 5.3% ▲ 1461.6%
Blackrock, Inc. $30.8M 3.0M 5.3% ▲ 538.4%
Deep Track Capital, LP $28.6M 2.8M 4.9% New
Vanguard Capital Management LLC $25.8M 2.5M 4.5% ▲ 40.2%
Opaleye Management Inc. $24.2M 2.3M 4.2% New
Millennium Management LLC $21.3M 2.1M 3.7% ▲ 18.1%
UBS Group AG $20M 1.9M 3.5% ▲ 2427.4%
Marshall Wace, LLP $18.5M 1.8M 3.2% ▲ 9.3%
Price T Rowe Associates Inc $17.9M 1.7M 3.1% ▲ 319.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Immix Biopharma, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $10,042 2 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $10,042 net buying
Insider Date Trade Shares Price Value
Morris Gabriel S CFO December 10, 2025 Buy 770 $6.58 $5,067
Rachman Ilya M CEO and Chairman December 10, 2025 Buy 746 $6.67 $4,976

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Immix Biopharma, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Immix Biopharma, Inc. in brief

What does Immix Biopharma, Inc. do?
Immix Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Immix Biopharma, Inc.'s stock ticker?
Immix Biopharma, Inc. trades under the ticker IMMX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Immix Biopharma, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jupiter Topco LLC, Saturn V Capital Management LP and Eventide Asset Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Immix Biopharma, Inc. stock?
Over the last 12 months, Immix Biopharma, Inc.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Immix Biopharma, Inc.'s next earnings date?
Around November 6, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Immix Biopharma, Inc. announces its own schedule.